Clovis Oncology, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense
Depreciation and amortization
Amortization of premiums and discounts on available-for-sale securities
Amortization of debt issuance costs
Write-off of debt issuance costs related to convertible senior notes transactions
Loss on convertible senior notes conversion
Loss on extinguishment of debt
Loss on sale of property and equipment
Deferred income taxes
Legal settlement loss
Impairment of intangible asset
Change in fair value of contingent purchase consideration
Loss on disposal of property and equipment
Acquired in-process research and development
Other
Changes in operating assets and liabilities:
Accounts receivable
Inventory
Prepaid and accrued research and development expenses
Deposit on inventory
Other operating assets and liabilities
Accounts payable
Other accrued expenses

Net cash used in operating activities
Investing activities
Purchases of property and equipment
Proceeds from sale of property and equipment
Deposits for sale of property and equipment
Purchases of available-for-sale securities
Sales of available-for-sale securities
Acquired in-process research and development - milestone payment
Net cash (used in) provided by investing activities

Financing activities
Proceeds from sale of common stock, net of issuance costs
Proceeds from issuance of convertible senior notes, net of issuance costs
Payment of convertible senior notes
Extinguishment of convertible senior notes
Proceeds from borrowings under financing agreement
Proceeds from the exercise of stock options and employee stock purchases
Payments on finance leases
Payments on other long-term liabilities
Net cash provided by financing activities
Increase (decrease) in cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents
(Decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information:
Cash paid for interest
Non-cash investing and financing activities:
Acquired in-process research and development - milestone not paid as of period end
Vesting of restricted stock units
Equipment acquired under capital lease

Comments